Tianhao Mu

Dr. Tianhao Mu


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2020 in Communications Biology
Verified
Journal Article
Open access
PDF file
TMTianhao Mu
Tianhao Mu
LXLiqin Xu
Liqin Xu
YZYu ZHONG
Yu ZHONG
XLXinyu Liu
Xinyu Liu
ZZZhikun Zhao
Zhikun Zhao
YHYong Hou
Yong Hou
The liver and gallbladder are among the most important internal organs derived from the endoderm, yet the development of the liver and gallbladder in the early embryonic stages is not fully understood. Using a transgenic Foxa2eGFP reporter mouse line, we performed single-cell full-length mRNA sequencing on endodermal and hepatic cells isolated from ten embryonic stages, ranging from E7.5 to E15.5. We identified the embryonic liver developmental trajectory from gut endoderm to hepatoblasts and characterized the transcriptome of the hepatic lineage. More importantly, we identified liver primordium as the nascent hepatic progenitors with both gut and liver features and documented dynamic gene expression during the epithelial-hepatic transition (EHT) at the stage of liver specification during E9.5–11.5. We found six groups of genes switched on or off in the EHT process, including diverse transcripitional regulators that had not been previously known to be expressed during EHT. Moreover, we identified and revealed transcriptional profiling of gallbladder primordium at E9.5. The present data provides a high-resolution resource and critical insights for understanding the liver and gallbladder development.

19 May 2020 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
YSYixun Su
Yixun Su
WZWenjun Zhang
Wenjun Zhang
CPC. Pawan K. Patro
C. Pawan K. Patro
JZJing Zhao
Jing Zhao
TMTianhao Mu
Tianhao Mu
YZYi Zhou
Yi Zhou
The proliferation and differentiation of neural progenitor lay the foundation for brain development. In neural progenitors, activation of Signal Transducer and Activator of Transcription 3 (STAT3) has been found to promote proliferation and astrocytogenesis while suppressing neurogenesis. However, our study found that Stat3 conditional knockout in neural progenitors (Stat3 cKO) also results in increased proliferation and suppressed neurogenesis. To investigate how STAT3 regulates these processes, we attempted to identify potential STAT3 target genes by RNA-seq profiling of the control (CTL) and Stat3 cKO neural progenitors. We found that STAT3 promotes the expression of genes involved in the mitochondrial oxidative phosphorylation (OXPHOS), and thereby promotes mitochondrial respiration and negatively regulates reactive oxygen species (ROS) production. In addition, we demonstrated that Stat3 loss-of-function promotes proliferation via regulation of mitochondrial metabolism and downstream signaling pathways. Our study provides novel insights into the relation between STAT3, mitochondrial metabolism and the process of embryonic neurogenesis.

30 August 2017 in Thoracic Cancer
Verified
Journal Article
Open access
PDF file
YYYang Yang
Yang Yang
TMTianhao Mu
Tianhao Mu
TLTe Li
Te Li
SXSongbo Xie
Songbo Xie
JZJun Zhou
Jun Zhou
DLDengwen Li
Dengwen Li
Background: Treatments that prevent the motility of breast cancer cells and inhibit formation of new capillary vessels are urgently needed. FSTL1 is a secreted protein that has been implicated in maintaining the normal physiological function of the cardiovascular system, in addition to a variety of other biological functions. We investigated the role of FSTL1 in the proliferation and migration of breast cancer and vascular endothelial cells.Methods: Human umbilical vein endothelial cells and human breast cancer BT‐549 cells were used to test the effects of FSTL1 and the N‐terminal domain of FSTL1. Immunofluorescence microscopy and 3‐(4, 5‐dimethylthiazolyl‐2)‐2,5‐diphenyltetrazolium bromide, transwell invasion, and wound healing assays were conducted.Results: Different doses of the N‐terminal fragment of FSTL1 (FSTL‐N) have variable effects on the migration of these cells. However, FSTL1 does not significantly affect tube formation in vitro from vascular endothelial cells. FSTL1‐FL and FSTL1‐N have modest effects on the invasion of breast cancer and vascular endothelial cells. Interestingly, FSTL1‐FL, but not FSTL‐N, modulates vascular endothelial cell polarization.Conclusion: FSTL1 modestly affects the proliferation of breast cancer cells and vascular endothelial cells. Our findings improve our understanding of the functions of FSTL1 in breast cancer development and angiogenesis.

31 January 2013 in Cell Biology International
Verified
Journal Article
Closed access
PDF file
QWQiang Wu
Qiang Wu
WZWei Zhang
Wei Zhang
TMTianhao Mu
Tianhao Mu
TSTianqiang Song
Tianqiang Song
DLDengwen Li
Dengwen Li

20 May 2020 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
YJYong Jiang
Yong Jiang
SDShiying Dang
Shiying Dang
LYLi Yang
Li Yang
YHYin Han
Yin Han
YZYongshen Zhang
Yongshen Zhang
FKFeng-Ming Kong
Feng-Ming Kong
E21043 Background: Homologous recombination (HR) is an important repair method for DNA double-strand damage. HR is involved with complex signaling pathways and multiple steps, including BRCA1/2. Homologous Recombination Deficiency (HRD) can be caused by the loss of function of BRCA1/2 proteins due to gene mutation. Tumor mutational burden (TMB) was indicated to involved with HRD, which is critical to the guidance of immunotherapy. Methods: Patients available with tumor specimen genomic testing for lung cancer were enrolled in this study. The sequencing library was captured using a 605-gene panel. Homologous recombination (HR)-related gene list included 102 genes. Genomic alterations of HR-related genes were assessed by next-generation sequencing assay, including nonsense, nonstop, frameshift, splice site, damaging missense mutations in somatic variants and pathogenic germline variants. Then, TMB was calculated by dividing the total number of mutations counted by the size of the coding region. Results: A total of 741 patients was enrolled and 182 of them (25.6%) had at least one genomic alteration of the HR genes. The top mutant HR genes included ATM (4.1%), DNMT3A (2.8%), ATR (1.8%), CHEK2 (1.5%), BRCA2 (1.5%), ABL1 (1.4%), FANCA (1.2%), RIF1 (1.1%), FANCI (1.1%), RAD50 (0.9%), BRCA1 (0.9%), and MRE11A (0.9%). The most common mutational type was missense mutation (69.2%), followed by frameshift (15.6%), and nonsense mutation (15.2%). The median age was 62 in the HRD group (age < 45:5.4%, 45-65:59.6%, > 65:34.9%) compared to 60 in the rest of the patients (age < 45:11.3%, 45-65:61.3%, > 65:27.4%). There were overall 57.5% males and 42.5% females in terms of gender. HRD group had a significantly higher rate than Non-HRD group in males (72.1% vs 52.8%, p < 0.01). The occurrence of HRD mutations was significantly correlated with a high level of TMB (p < 0.01). The median TMB of HRD group (7.9 muts/Mb, 95%CI:7.1-9.2 muts/Mb) was significantly higher than that of Non-HRD group (3.8 muts/Mb, 95%CI:3.3-4.2 muts/Mb). In addition, the upper quantile value (7.5 muts/Mb) was used to identify patients with high TMB. HRD group had a significantly higher rate of TMB-high patients than Non-HRD group (51.1% vs 17.0%, p < 0.01). Conclusions: Our study demonstrated genomic alterations of the HR genes in about one fourth’s lung cancer. Besides, there was a significant positive correlation between HRD mutations and TMB level. The significance of HRD genomic mutation on predicting the efficacy of immunotherapy deserves further study.

5 March 2020 in Cellular & Molecular Immunology
Verified
Journal Article
Closed access
PDF file
ZMZhongnan Ma
Zhongnan Ma
NSNa Sheng
Na Sheng
XLXinyu Liu
Xinyu Liu
YSYixun Su
Yixun Su
YZYi Zhou
Yi Zhou
XFXin-Yuan Fu
Xin-Yuan Fu